Low monocytes shows a huge improvement and under65 is significant.
I don’t think the market fully appreciates these results and the monetary potential. Everyone is looking for the silver bullet, when the reality is different bullets for different patient groups.
At a minimum, if Efti increases life expectancy by nearly two years in 20% of mbc patients and providing better quality of life then it’s a BLOCKBUSTER drug. No ifs-or buts.
And that is only scratching the surface of Efti potential.
I’ll be referring to Efti as a blockbuster in the making from now on.
Low monocytes shows a huge improvement and under65 is...
-
- There are more pages in this discussion • 102 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
42.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $598.3M | |||
| Open | High | Low | Value | Volume |
| 41.5¢ | 42.5¢ | 41.0¢ | $1.132M | 2.721M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 15565 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.5¢ | 246989 | 7 |
View Market Depth
| Last trade - 16.10pm 25/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |